VIDEO: Adjuvant pembrolizumab may be ‘game changer’ in some patients with RCC
Click Here to Manage Email Alerts
In this video, Mark W. Ball, MD, discusses updates from the KEYNOTE-564 study on the use of adjuvant pembrolizumab in certain patients with renal cell carcinoma presented at the 2022 ASCO Genitourinary Cancers Symposium.
Ball, who is the associate program director of the Urologic Oncology Fellowship and assistant research physician in the Urologic Oncology Branch of the National Cancer Institute, noted that findings presented at the meeting were a 30-month update of the study, which was originally published last year.
“What we saw [was] continuing separation of the curve between patients who received adjuvant pembrolizumab vs. those who did not in terms of a progression-free survival benefit,” Ball said. “I think that the overall survival curves are beginning to separate — they’re not statistically significantly different yet, but it appears with more time that we could see a significant difference in overall survival, which I think could be a game changer for patients at high risk of recurrence after nephrectomy.”
Collapse
Healio Interview
Choueiri TK, et al. Abstract 290. Presented at: ASCO Genitourinary Cancers Symposium; Feb. 17-19, 2022; San Francisco.
Read more about
Click Here to Manage Email Alerts